PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsFomepizole
Fomepizole
Antizol (fomepizole) is a small molecule pharmaceutical. Fomepizole was first approved as Antizol on 1997-12-04. It is used to treat poisoning in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
chemically-induced disordersD064419
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Fomepizole
Tradename
Company
Number
Date
Products
ANTIZOLPar PharmaceuticalN-020696 DISCN1997-12-04
1 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
antizolNew Drug Application2009-07-27
fomepizoleANDA2023-10-26
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
poisoningEFO_0008546D011041T65.91
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Fomepizole, Antizol, Par Pharm Inc
75538632027-06-30DS, DP
ATC Codes
V: Various drug classes in atc
— V03: All other therapeutic products
— V03A: All other therapeutic products
— V03AB: Antidotes
— V03AB34: Fomepizole
HCPCS
Code
Description
J1451
Injection, fomepizole, 15 mg
Clinical
Clinical Trials
119 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Multiple myelomaD009101—C90.02331—7
Plasma cell neoplasmsD054219——2331—7
Crohn diseaseD003424EFO_0000384K50———2—2
ColitisD003092EFO_0003872K52.9—1—1—2
Systemic lupus erythematosusD008180HP_0002725M32—1—1—2
Type 2 diabetes mellitusD003924EFO_0001360E11———1—1
Diabetes mellitusD003920HP_0000819E08-E13———1—1
Ulcerative colitisD003093EFO_0000729K51———1—1
UlcerD014456MPATH_579————1—1
FibrosisD005355—————1—1
Show 2 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LeukemiaD007938—C9532128—150
Precursor cell lymphoblastic leukemia-lymphomaD054198——32223—247
Lymphoid leukemiaD007945—C9132121—244
LymphomaD008223—C85.9166——11
Non-hodgkin lymphomaD008228—C85.9154——9
Precursor t-cell lymphoblastic leukemia-lymphomaD054218——134——7
Philadelphia chromosomeD010677———33——6
Promyelocytic leukemia acuteD015473—C92.4——4——4
Down syndromeD004314EFO_0001064Q90—22——4
SyndromeD013577———21—14
Show 15 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369—C8021——14
RecurrenceD012008——13———3
Parkinson diseaseD010300EFO_0002508G20—1——23
Prostatic neoplasmsD011471—C61—1——23
AnemiaD000740HP_0001903D64.912———2
Fanconi anemiaD005199Orphanet_84D61.0912———2
Eye diseasesD005128EFO_0003966H44—1——12
Colorectal neoplasmsD015179———1———1
Precursor b-cell lymphoblastic leukemia-lymphomaD015452———1———1
Hermanski-pudlak syndromeD022861—E70.331—1———1
Show 22 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Macular degenerationD008268EFO_0001365H35.301———12
Stargardt diseaseD000080362—H35.531————1
Hereditary corneal dystrophiesD003317HP_0007802H18.51————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Kidney diseasesD007674EFO_0003086N08————33
GlaucomaD005901EFO_0000516H40————33
Respiratory tract infectionsD012141—J06.9————11
InfectionsD007239EFO_0000544—————11
Communicable diseasesD003141——————11
Mycoplasma infectionsD009175——————11
PleuropneumoniaD011001——————11
Choroidal neovascularizationD020256——————11
Pathologic neovascularizationD009389——————11
AnesthesiaD000758——————11
Show 35 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameFomepizole
INNfomepizole
Description
Fomepizole is a member of the class of pyrazoles that is 1H-pyrazole substituted by a methyl group at position 4. It has a role as an antidote, a protective agent and an EC 1.1.1.1 (alcohol dehydrogenase) inhibitor. It derives from a hydride of a 1H-pyrazole.
Classification
Small molecule
Drug class—
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
Cc1cn[nH]c1
Identifiers
PDB—
CAS-ID7554-65-6
RxCUI—
ChEMBL IDCHEMBL1308
ChEBI ID5141
PubChem CID3406
DrugBankDB01213
UNII ID83LCM6L2BY (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 1,060 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
124 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use